Press Releases

Circassia Appoints Industry Veteran Jonathan Emms as Chief Operating Officer

Click here to download the full press release – COO to join Board and SVP R&D to step down as Director reflecting Company’s commercial focus – Oxford, UK – 12 August 2019: Circassia Pharmaceuticals plc...

View details

Circassia Announces Publication of Tudorza® Phase IV ASCENT Study in the Journal of the American Medical Association

Click here to download full press release Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication...

View details

Preliminary Results for the Year Ended 31 December 2018

Click here to download the full 2018 preliminary results statement Oxford, UK – 1 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces...

View details

Circassia Announces FDA Approval of Duaklir® for Maintenance Treatment of Chronic Obstructive Pulmonary Disease

Click here to download the full press release – Duaklir® launch planned H2 2019 – – Duaklir® to join Tudorza® in Circassia’s portfolio of US COPD products – Oxford, UK – 1 April 2019: Circassia...

View details

Circassia Announces FDA Approval of Tudorza® Supplemental New Drug Application

This announcement contains inside information for purposes of Article 7 of Market Abuse Regulation 596/2014 Click here to download the full press release – Data showing reduction in COPD exacerbations and no increase in major...

View details

Circassia Announces Successful Completion of FDA Pre-submission Meeting for Novel Nitric Oxide Product AirNOvent

Click here to download the full press release Oxford, UK – 4 February 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces its partner,...

View details

Circassia to Acquire US and Chinese Commercialisation Rights to Novel Nitric Oxide Product AirNOvent from AIT Therapeutics Inc.

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014 Click here to download the full press release Oxford, UK – 24 January 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”;...

View details

Circassia to Exercise Option for Full US Commercial Rights to COPD Treatment Tudorza® from AstraZeneca

Click here to download the full press release Oxford, UK – 11 December 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces it has...

View details

Interim Results for the Six Months Ended 30 June 2018

Click here to download the full 2018 interim results – NIOX® sales growth continued – – Tudorza® profit share revenues increased – – Duaklir® NDA and Tudorza® sNDA accepted for review by FDA – –...

View details

Circassia Announces Duaklir® New Drug Application (NDA) and Tudorza® Supplemental NDA Accepted for Review by FDA

Click here to download full press release – PDUFA target action date of 31 March 2019 confirmed for both filings – Oxford, UK – 13 August 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR),...

View details